Home About us Contact
|
Home About us Contact | ||
|
|
||
Surgical Oncology (surgical + oncology)
Selected AbstractsMAGNETIC RESONANCE IN SURGICAL ONCOLOGY: I , ON THE ORIGIN OF THE SPECTRUMANZ JOURNAL OF SURGERY, Issue 6 2005Laurence Gluch The discovery of the phenomenon of nuclear magnetic resonance occurred just 60 years ago. The profusion of subsequent discoveries in this domain has led to the development of magnetic resonance spectroscopy , refined as an analytical tool to discern molecular structure , and magnetic resonance imaging, a cornerstone of modern radiology. Observable alterations in cellular structure and metabolism can be discerned using the non-destructive chemical analysis of magnetic resonance spectroscopy in vitro or in vivo. Differences may thus be discerned between malignant and normal tissues. [source] MAGNETIC RESONANCE IN SURGICAL ONCOLOGY: II , LITERATURE REVIEWANZ JOURNAL OF SURGERY, Issue 6 2005Laurence Gluch Ex vivo and in vivo applications of magnetic resonance spectroscopy have been developed which aid in distinguishing malignant from normal tissues. Studies of breast, colon, cervix, oesophageal and prostate cancer reveal both the successes and failings of present technology. Verification that these non-invasive tests might supplant conventional histology in obtaining spatial diagnostic and chemical prognostic information remains for the time being illusive. [source] International Society of Paediatric Surgical Oncology, IPSO XXXIII Meeting, Brisbane, Australia, October 10,13, 2001PEDIATRIC BLOOD & CANCER, Issue 3 2001Article first published online: 31 AUG 200 First page of article [source] Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug deliveryJOURNAL OF PHARMACY AND PHARMACOLOGY: AN INTERNATI ONAL JOURNAL OF PHARMACEUTICAL SCIENCE, Issue 2 2002Eugene P. Goldberg The recent literature documents the growing interest in local intratumoral chemotherapy as well as systemic preoperative chemotherapy with evidence for improved outcomes using these therapeutic modalities. Nevertheless, with few exceptions, the conventional wisdom and standard of care for clinical and surgical oncology remains surgery followed by radiation and/or systemic chemotherapy, as deemed appropriate based on clinical findings. This, in spite of the fact that the toxicity of conventional systemic chemotherapy and immunotherapy affords limited effectiveness and frequently compromises the quality of life for patients. Indeed, with systemic chemotherapy, the oncologist (and the patient) often walks a fine line between attempting tumour remission with prolonged survival and damaging the patient's vital functions to the point of death. In this context, it has probably been obvious for more than 100 years, due in part to the pioneering work of Ehrlich (1878), that targeted or localized drug delivery should be a major goal of chemotherapy. However, there is still only limited clinical use of nonsystemic intratumoral chemotherapy for even those high mortality cancers which are characterized by well defined primary lesions i.e. breast, colorectal, lung, prostate, and skin. There has been a proliferation of intratumoral chemotherapy and immunotherapy research during the past two to three years. It is therefore the objective of this review to focus much more attention upon intratumoral therapeutic concepts which could limit adverse systemic events and which might combine clinically feasible methods for localized preoperative chemotherapy and/or immunotherapy with surgery. Since our review of intratumoral chemo-immunotherapy almost 20 years ago (McLaughlin & Goldberg 1983), there have been few comprehensive reviews of this field; only one of broad scope (Brincker 1993), three devoted specifically to gliomas (Tomita 1991; Walter et al. 1995; Haroun & Brem 2000), one on hepatomas (Venook 2000), one concerning veterinary applications (Theon 1998), and one older review of dermatological applications (Goette 1981). However, none have shed light on practical opportunities for combining intratumoral therapy with subsequent surgical resection. Given the state-of-the-art in clinical and surgical oncology, and the advances that have been made in intratumoral drug delivery, minimally invasive tumour access i.e. fine needle biopsy, new drugs and drug delivery systems, and preoperative chemotherapy, it is timely to present a review of studies which may suggest future opportunities for safer, more effective, and clinically practical non-systemic therapy. [source] Measuring and reporting on quality in health care: A framework and road map for improving careJOURNAL OF SURGICAL ONCOLOGY, Issue 8 2009Susan E. Brien PhD Abstract Quality of care measurement and reporting at the provider, hospital, or health system level has become increasingly common in health systems around the world. Health system performance reports, whether they be confidentially distributed to the provider or made available to the public, are not only used as a stimulus for quality improvement, but can also be used to inform policy, apportion funding, or in rare cases, punish poorly performing providers. In this review, we outline several principles of quality of healthcare measurement and performance reporting, and describe a framework for optimal performance reporting that provides the greatest opportunity for the desired outcome,health system improvement. The quality reporting framework and roadmap that we present invokes opportunities for improving care in the domain of surgical oncology. J. Surg. Oncol. 2009;99:462,466. © 2009 Wiley-Liss, Inc. [source] Management of lentigo maligna and lentigo maligna melanoma: Seminars in surgical oncology,JOURNAL OF SURGICAL ONCOLOGY, Issue 4 2004FRCPC, John P. Arlette MD Abstract Lentigo maligna (LM) and lentigo maligna melanoma (LMM) represent a character, histogenetic subclass of melanocytic malignancies. They often present with a prolonged phase of slow growth but once invasion has occurred, the prognostic features are identical to all other melanomas. These lesions occur primarily on the head and neck where they evolve from areas of pigmented staining to the more typical features identifiable with malignant melanomas on other skin surfaces. The treatment options and recent advances in management are reviewed. J. Surg. Oncol. 2004;86:179,186. © 2004 Wiley-Liss, Inc. [source] Global issues in surgical oncologyJOURNAL OF SURGICAL ONCOLOGY, Issue 2 2003FRCSC, Walley J. Temple MD No abstract is available for this article. [source] Thoracic surgical oncology: exposures and techniques.BRITISH JOURNAL OF SURGERY (NOW INCLUDES EUROPEAN JOURNAL OF SURGERY), Issue 6 2004Gary C. Wind., Jonothan C. Nesbitt No abstract is available for this article. [source] Significance of apoptosis in surgical oncologyBRITISH JOURNAL OF SURGERY (NOW INCLUDES EUROPEAN JOURNAL OF SURGERY), Issue 2 2003A. I. Sarela Improved prognostic information and anticancer agents [source] | |||||||||||||||||||